Mazdutide

People run it for fat loss, with two reported signatures the rest of the GLP-1 class is quieter on: a metabolic-rate lift from the glucagon arm, and a strong pull on liver fat. The usual appetite suppression and “food noise” drop are there too. It’s one of the few peptides here with real Phase-2 and Phase-3 trial data for the exact use people run it for — but almost all of that data is in Chinese adults.

Its identity is the second receptor it picks. The two-receptor drug most people know (tirzepatide) pairs GLP-1 with GIP; mazdutide pairs GLP-1 with glucagon instead. GIP is mostly another appetite/insulin lever, while glucagon is an energy-expenditure and liver lever — so the community description shifts from “appetite drug” toward “appetite drug that also turns the furnace up.” The most-repeated talking points are the liver-fat reduction and a reported bump in resting energy use; the loudest caveat is that the published proof is concentrated almost entirely in one region’s trials, so how it generalizes is still an open question.

A dual agonist built on the oxyntomodulin scaffold: it activates the GLP-1 receptor (appetite suppression, slowed gastric emptying, better glucose handling) and the glucagon receptor (raised energy expenditure plus mobilization of hepatic fat). That glucagon arm is the contrast with the GIP-based duals — instead of stacking a second appetite/insulin signal, it adds a catabolic, fat-burning one. The trade-off is that glucagon-receptor activation is also what can nudge heart rate, fasting glucose, and the liver, which is why it’s a more “active” molecule than a pure GLP-1.

GI is the dominant story, as with the whole class: nausea, diarrhea, decreased appetite, vomiting, and abdominal distension, mostly mild-to-moderate and worst during titration. The glucagon arm adds its own considerations on top — a small resting-heart-rate increase, and transient rises in fasting glucose and liver enzymes reported in trials (the glucagon receptor acts directly on the liver). As with every GLP-1-class drug, rapid weight loss means muscle loss unless protein and resistance training are in place, and the usual class cautions apply (pancreatitis signal, gallbladder, and the rodent thyroid-tumor flag that follows the whole family). Trial tolerability has been reasonable — but it’s trial tolerability, in one population.

Run standalone for fat loss — there’s no community peptide-stacking protocol, and stacking it with another GLP-1-class drug just multiplies the GI and glucagon load. As with the triple agonist, “stack” here means the support around it: high protein and resistance training to defend muscle, plus electrolytes and micronutrients. The work is in diet and training alongside it, not in pairing vials.